Brookstone Capital Management Has $2.65 Million Holdings in United Therapeutics Corporation $UTHR

Brookstone Capital Management lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 32.5% during the first quarter, Holdings Channel.com reports. The institutional investor owned 4,471 shares of the biotechnology company’s stock after selling 2,151 shares during the quarter. Brookstone Capital Management’s holdings in United Therapeutics were worth $2,651,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of UTHR. Torren Management LLC bought a new position in United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC raised its position in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics in the fourth quarter worth $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent research reports. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, HC Wainwright lifted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Stock Performance

United Therapeutics stock opened at $549.66 on Thursday. The stock has a fifty day moving average of $562.63 and a 200-day moving average of $525.08. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The stock has a market capitalization of $23.33 billion, a P/E ratio of 20.29, a price-to-earnings-growth ratio of 1.80 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the firm posted $6.63 earnings per share. On average, research analysts forecast that United Therapeutics Corporation will post 26.49 earnings per share for the current year.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $541.55, for a total value of $4,494,865.00. Following the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at $24,462,896.60. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $537.74, for a total value of $5,108,530.00. Following the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at $21,785,460.62. The trade was a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 633,718 shares of company stock worth $358,492,749. Insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.